Literature DB >> 6088253

Omeprazole, a gastric 'proton pump inhibitor': lack of effect on renal handling of electrolytes and urinary acidification.

C W Howden, J L Reid.   

Abstract

Omeprazole has previously been shown to be a potent inhibitor of gastric acid secretion in man. In a new study, oral omeprazole 60 mg/day was given to 8 healthy male subjects for 8 days. The daily urinary electrolyte output and urine pH in response to ammonium chloride were not significantly altered. This provides further support for the specificity of its action on gastric acid secretion.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6088253     DOI: 10.1007/bf00543501

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  6 in total

1.  Effects of single and repeated doses of omeprazole on gastric acid and pepsin secretion in man.

Authors:  C W Howden; J A Forrest; J L Reid
Journal:  Gut       Date:  1984-07       Impact factor: 23.059

2.  Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+)ATPase.

Authors:  E Fellenius; T Berglindh; G Sachs; L Olbe; B Elander; S E Sjöstrand; B Wallmark
Journal:  Nature       Date:  1981-03-12       Impact factor: 49.962

3.  Rapid healing of duodenal ulcers with omeprazole: double-blind dose-comparative trial.

Authors:  S Gustavsson; H O Adami; L Lööf; A Nyberg; O Nyrén
Journal:  Lancet       Date:  1983-07-16       Impact factor: 79.321

4.  Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man.

Authors:  T Lind; C Cederberg; G Ekenved; U Haglund; L Olbe
Journal:  Gut       Date:  1983-04       Impact factor: 23.059

5.  Effect of daily oral omeprazole on 24 hour intragastric acidity.

Authors:  R P Walt; M D Gomes; E C Wood; L H Logan; R E Pounder
Journal:  Br Med J (Clin Res Ed)       Date:  1983-07-02

6.  Characterization of gastric mucosal membranes. X. Immunological studies of gastric (H+ + K+)-ATPase.

Authors:  G Saccomani; H F Helander; S Crago; H H Chang; D W Dailey; G Sachs
Journal:  J Cell Biol       Date:  1979-11       Impact factor: 10.539

  6 in total
  13 in total

Review 1.  PPIs and kidney disease: from AIN to CKD.

Authors:  Dennis G Moledina; Mark A Perazella
Journal:  J Nephrol       Date:  2016-04-12       Impact factor: 3.902

Review 2.  Safety of acid-suppressing drugs.

Authors:  R A Smallwood; R G Berlin; N Castagnoli; H P Festen; C J Hawkey; S K Lam; M J Langman; P Lundborg; A Parkinson
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

Review 3.  Omeprazole. Overview and opinion.

Authors:  S Holt; C W Howden
Journal:  Dig Dis Sci       Date:  1991-04       Impact factor: 3.199

4.  Antisecretory effect and oral pharmacokinetics of omeprazole in patients with chronic renal failure.

Authors:  C W Howden; C D Payton; P A Meredith; D M Hughes; A I Macdougall; J L Reid; J A Forrest
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 5.  Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.

Authors:  S P Clissold; D M Campoli-Richards
Journal:  Drugs       Date:  1986-07       Impact factor: 9.546

Review 6.  Renal effects of peptic ulcer therapy.

Authors:  E Burgess; D Muruve
Journal:  Drug Saf       Date:  1992 Jul-Aug       Impact factor: 5.606

7.  Electrolyte disturbance with omeprazole therapy.

Authors:  C Melville; A Shah; D Matthew; P Milla
Journal:  Eur J Pediatr       Date:  1994-01       Impact factor: 3.183

8.  A double-blind placebo-controlled trial of omeprazole on urinary pH in healthy subjects.

Authors:  P J Osther; L Rasmussen; S A Pedersen
Journal:  Int Urol Nephrol       Date:  1992       Impact factor: 2.370

Review 9.  Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure.

Authors:  U Gladziwa; U Koltz
Journal:  Clin Pharmacokinet       Date:  1994-11       Impact factor: 6.447

10.  [Follow-up care - consequences of urinary diversion after bladder cancer].

Authors:  S Degener; S Roth; M J Mathers; B Ubrig
Journal:  Urologe A       Date:  2014-02       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.